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Abstract
Previously, 31P magnetic resonance spectroscopy
(MRS) has been used to detect ifosfamide ( IF) in vivo
and to show that breathing carbogen (5% CO2/95% O2)
enhances the uptake and increases the efficacy of IF in
rat GH3 prolactinomas [Rodrigues LM, Maxwell RJ,
McSheehy PMJ, Pinkerton CR, Robinson SP, Stubbs M,
and Griffiths JR (1997). In vivo detection of ifosfamide
by 31P MRS in rat tumours; increased uptake and
cytotoxicity induced by carbogen breathing in GH3
prolactinomas. Br J Cancer 75, 62–68]. We now show
that other hypercapnic and/or hyperoxic (5% CO2 in air,
2.5%CO2 in O2) gasmixtures also increase the uptake of
IF into tumors, measured by 31P MRS. All gases caused
an increased uptake (Cmax) of IF compared to air
breathing, with carbogen inducing the largest increase
(85% (P<.02) compared to 46% with 2.5% CO2 in O2
(P<.004) and 48% with 5% CO2 in air (P<.004)). The
Tmax (time of maximum concentration in tumor posin-
travenous injection of IF) was significantly (P<.04) later
in the cohort that breathed 5% CO2 in air. The increased
uptake of IF with carbogen breathing was selective to
tumor tissue and there were no significant increases in
any of the normal tissues studied, suggesting that any
host tissue toxicity would be minimal. Carbogen breath-
ing by patients causes breathlessness. There was no
significant difference in IF uptake between breathing
carbogen and 2.5% CO2 in O2 and, therefore, the ability
of 2.5% CO2 in O2 to also increase IF uptake may be
clinically useful as it causes less patient discomfort.
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Introduction
The inadequacy of tumor vasculature is a major disadvant-
age with regard to the efficacy of both chemotherapy and
radiotherapy. In chemotherapy, where tumor blood flow is
usually a vehicle for delivery of therapeutic agents, a reduced
blood flow or volume within the tumor will limit the delivery of
these agents. Reduced tumor oxygenation or presence of
hypoxic tissue renders the tumor more resistant to radio-
therapy and because oxygen is supplied to the tumor through
the blood flow, a reduced blood flow or volume will reduce the
efficacy of radiotherapy. The physiological factors that could
contribute to the reduced therapeutic effect include a hetero-
geneous and immature blood supply, reduced vessel size
and diameter, and greater transport distances across the
interstitium. These physiological barriers limit access of drugs
to many parts of the tumor both through inadequate drug
uptake and nonoptimal distribution, and also render the tumor
radioresistant [1 ].
Several physical factors (e.g., hyperthermia, radiation)
and chemical modifiers (e.g., vasoactive drugs) have been
used to increase tumor blood flow to enhance therapeutic
response [2]. Recently, carbogen (5% CO2/95% O2)
breathing has been shown to increase both blood oxygen-
ation/ flow [3,4 ] and blood volume of tumors [5], thereby
increasing radiosensitivity [6 ] and enhancing the effective-
ness of chemotherapy [7,8].
Carbogen was originally used as an adjuvant for radio-
therapy to reoxygenate hypoxic tissue. The CO2 component
was incorporated with oxygen to provide a more physiological
environment and also to act as a vasodilator to prevent the
hyperoxic vasoconstriction of blood vessels [6,9].
Numerous studies have recently shown the effect of
carbogen breathing on tumor physiology, metabolism, and
therapy. In particular, noninvasive blood oxygen level–
dependent magnetic resonance imaging (BOLD MRI) has
been used to show increases in tumor blood oxygenation with
carbogen breathing both in preclinical [3 ] and clinical [10,11]
studies. Changes in tumor metabolism have also been
reported: breathing carbogen has been shown by 31P
magnetic resonance spectroscopy (MRS) to change tumor
pH and energy status and by non-MR methods to increase
blood glucose and decrease tumor lactate [12].
19F and 31P MRS have been used to study the phar-
macokinetics and pharmacodynamics of fluorinated drugs,
e.g., 5- fluorouracil (5FU) [13], and phosphorus-containing
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drugs, e.g., ifosfamide ( IF) [7 ], noninvasively, in vivo. This
method has the potential of tailoring treatment to an
individual patient. Carbogen breathing before and during
drug administration has been shown by MRS to increase the
uptake [8,14] and enhance the efficacy of 5FU [8] and IF [7]
in experimental tumors, and may therefore be useful in the
clinic for selectively increasing the uptake of chemother-
apeutic agents into tumors [10,15]. A disadvantage, how-
ever, of breathing carbogen in the clinic is the degree of
patient discomfort caused by breathing 5% CO2, where
patients are known to experience symptoms of breath-
lessness, probably due to the increased respiratory drive
caused by the CO2. Recent studies have shown that
inhalation of 2% CO2 in oxygen in clinical studies [16] and
2.5% CO2 in oxygen in preclinical studies [17] improves
oxygenation and radiosensitization of tumors as effectively
as carbogen. Moreover, the patients breathing 2% CO2 in
oxygen were reported to be more comfortable and found
breathing the gas easier. More recently, Thews et al. [4 ]
have shown that breathing gases with high CO2 fractions
(2.5% or 5%) leads to a prolonged improvement of tumor
pO2 and blood flow after the end of inspiratory hyperoxia
when compared to 100% O2. It has also been shown by
noninvasive BOLD MRI in rat GH3 prolactinomas that there
are similar increases in tumor blood oxygenation with 1%
and 2.5% CO2 in O2 to those seen with carbogen [18]. The
above studies all support the concept that the levels of CO2
in carbogen can be reduced without compromising the
enhanced oxygenation, radiosensitization, and blood flow of
tumor tissue. Could the same hold for the uptake of
chemotherapeutic agents?
It has previously been shown by in vivo 31P MRS that
breathing carbogen increases the uptake of the prodrug IF
into GH3 prolactinomas and enhances the efficacy of
treatment [7]. This was thought to be due to an increase in
tumor blood volume during carbogen breathing, which was
probably accompanied by an increased delivery of 4-
hydroxyifosfamide, the activated form of IF. Alternatively,
the tumor itself may be able to activate IF in situ as suggested
by cell culture studies [7]. The aim of this present study was,
firstly, to determine whether breathing hypercapnic and/or
hyperoxic gases with a lower CO2 content would still cause
an enhanced IF uptake and, secondly, to determine if the
enhanced uptake of IF with carbogen was solely due to the
vasodilative effects of CO2 on tumor blood vessels.
Materials and Methods
IF (Mitoxana; ASTA Medica, Cambridge, UK) was made up
freshly at a concentration of 100 mg/ml in normal saline, at
pH 7.2 to 7.4, and administered intravenously at a dose of
250 mg/kg, which is equivalent to 1.5 g/m2, using the
surface law formula [19]. If the animal was to recover from
the anaesthetic, MESNA (Uromitexan), a uroprotector was
administered intravenously (150 mg/kg).
Animals and Tumors
GH3 prolactinomas were grown subcutaneously in
the flanks of 180- to 200-g female Wistar Furth rats as
previously described [20]. Tumor volume was calculated
using the formula ((p /6)d1d2d3) and the mean tumor
volume for the MR experiments was 5.27±1.28 cm3. All
experiments were performed in accordance with the UK
Home Office Animals Scientific Procedures Act 1986.
31P MRS
Animals were anesthesized with pentobarbitone (40 mg/
kg) and maintained at 378C with a warm water blanket. The
tail vein was cannulated and an intravenous line placed for
administration of IF while the animal was in the magnet. 31P
MRS spectra were obtained on a 4.7T Varian Unity Inova
spectrometer with a 20-mm, two- turn surface coil. Non-
localized 31P spectra were obtained using an adiabatic
sincos pulse, TR of 3 s, and 64 or 128 acquisitions. Cohorts
of animals breathed air for up to 7 minutes and then either
certified gas mixtures of carbogen (n=4), 2.5% CO2 in
oxygen (n=5), or 5% CO2 in air (n=4) at a rate of 2 l /min for
10 minutes through a mask equipped with a scavenger. IF
was administered intravenously during the tenth minute of
each gas regime. Air breathing was resumed after each gas
regime. The control group of animals (n=3) breathed air
throughout the experiment. Spectra were acquired for up to
3 hours post - IF injection.
Quantitation of Spectra and Pharmacokinetic Analysis
Spectra were quantitated using VARPRO, a time
domain nonlinear least squares method [21]. The data
were fitted by assuming contributions from IF, phosphomo-
noesters (PME), inorganic phosphate (Pi ), phosphocrea-
tine (PCr), and the  - ,  - , and g -nucleoside triphosphate
(NTP) resonances. To normalize the data, the IF level was
expressed as a ratio of IF to total phosphate signal, i.e.,
sum of PME, Pi, PCr, and  - ,  - , and g -NTP in the signals
in the spectra, as total phosphate was unlikely to change
over the time course of the experiments. Tumor energetic
status was assessed by determining the  -NTP/Pi ratio,
and pH was calculated from the chemical shift of Pi relative
to  -NTP at 7.57 ppm according to Ref. [22].
The pharmacokinetic parameters of area under the curve
(AUC; IF/
P
P versus time), T1 / 2 (half - life [minutes] of IF in
tumor), and Cmax (maximum IF concentration by pharma-
cokinetic analysis) were computed from the IF/
P
P versus
time (minutes) curve using the PCNONLIN (Lexington, KY)
software, which provides a least squares estimate of the
parameters in a nonlinear model. The best fit was obtained
using a one-compartment model with bolus input and first -
order output using the equation:
CT ¼ D=V * exp(Kel *T)
where C=IF/
P
P, T=time (minutes), D=dose, V=volume,
and Kel=elimination rate. This yielded values of AUC, Cmax,
and T1 / 2 (0.693/Kel ) for each individual tumor.
31P MRS of Extracts
A separate cohort of GH3 tumor-bearing animals
(n=4) was anesthesized and breathed either air or
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carbogen for 10 minutes. IF was injected intravenously
(250 mg/kg) in the tenth minute, and after a further 15
minutes, the tumor, liver, spleen, muscle, kidney, heart,
and lung were excised and freeze-clamped. The frozen
tissues were ground in liquid nitrogen and extracted with
cold 6% perchloric acid, centrifuged, and the supernatants
neutralized. The neutralized extracts were freeze-dried
and taken up in 50 mM triethanolamine/15 mM EDTA
buffer containing 10% D2O and an internal standard of
2 mol of dimethyl methyl phosphonate (DMMP). 31P MRS
spectra were acquired on a Bruker AMX400 spectrometer
at 162 MHz with a spectral width of 70 kHz, a 308 flip angle,
0.5 s acquisition time, 3 s relaxation delay, and 512 scans. IF
levels were calculated relative to DMMP using peak
integrals.
Statistical Analysis
All results were presented as mean values ±1 SEM.
Comparisons between the groups were performed using the
two- tailed Student’s t - test. The significance level was set at
5%.
Results
IF resonates +18 ppm from PCr in the 31P MRS spectrum. It
was detected in all tumors, regardless of which gas the
animal was breathing, within a few minutes of an intravenous
injection (Figure 1) and was still detectable at the end of the
experiment, 3 to 4 hours later.
Effect of Carbogen, 2.5% CO2 in Oxygen, and 5% CO2 in Air
on IF Pharmacokinetics in GH3 Tumors
Compared to air breathing, all three gas regimes caused
significant increases ( ranging from 50% to 70%) in the
maximum observed IF concentration (expressed as a ratio of
IF to total phosphate, to normalize the data) and in Cmax
(maximum IF concentration by pharmacokinetic analysis) in
the tumor (Figure 2, A and B ). In contrast, Tmax ( time of the
maximum observed IF concentration in tissue) was signifi-
cantly later with 5%CO2 in air (22.4±1.8 minutes) compared
to air alone (13.9±2.5 minutes, P<.04), but not significantly
later with carbogen (12.8±3.7 minutes) or 2.5% CO2 in O2
Figure 1. Representative 31P MRS spectra of GH3 prolactinomas 12 minutes
after intravenous injection of IF (250 mg /kg ) in rats breathing (A ) air, (B ) 5%
CO2 in air, (C ) 2.5% CO2 in O2, and (D ) 5% CO2 in O2. Peak assignments
are as follows: (1 ) IF; ( 2 ) PME; ( 3 ) Pi; ( 4 ) phosphodiesters; ( 5 ) PCr; ( 6 ) g -
NTP; ( 7 )  -NTP; (8 )  -NTP.
Figure 2. Effect of breathing different gas mixtures on the (A ) maximum
observed IF ( IF /
P
P) and the (B ) Cmax (maximum IF /
P
P from pharmaco-
kinetic analysis ). Mean±SEM (n=3–5 ). *P< .02, **P< .004 compared to air
breathing.
Figure 3. Effect of breathing different gas mixtures on the Tmax ( time of
maximum observed IF /
P
P) in tissue as observed by 31P MRS. Mean±SEM
(n=3–5 ). *P< .04 compared to air breathing.
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(10.2±1.57 minutes) compared to air alone (Figure 3).
Changes in the other pharmacokinetic parameters, T1 / 2 and
AUC, were not significantly different (P>.1) between air
breathing and each of the gas regimes (Table 1). It should be
noted that in vivo 31P MRS detects only the prodrug IF and
not its activated form, 4-OH IF, and therefore, the measure
of Cmax rather than AUC may be more relevant to the tumor
response.
Effects of IF on Endogenous Tumor Phosphorus
Metabolites and Tumor pH with the Three Gas Regimes
A time course showed that prior to injection of IF, there
was a tendency for the  -NTP/Pi ratio to increase with 2.5%
CO2 in O2 and carbogen breathing, but not with 5%CO2 in air
breathing (Figure 4). Similar observations have been
previously made in GH3 prolactinomas with longer carbogen
breathing times [18]. However, within 40 minutes of IF
administration,  -NTP/Pi decreased with all gas regimes
(P<.04 with air breathing or 2.5% CO2 in O2; P<.1 with
carbogen or 5% CO2 in air breathing). The minimum level of
 -NTP/Pi post- IF injection was not significantly different
between the gas regimes, except between 5%CO2 in air and
2.5%CO2 in O2 (P=.04), which could be a consequence of a
significantly longer Tmax with 5%CO2 in air. There was also a
concomitant fall in pH of between 0.05 and 0.15 pH units with
all gas regimes (P<.05 with carbogen and 5% CO2 in air )
post- IF injection with recovery within 2 to 4 hours (Figure 4).
As previously reported, this fall in  -NTP/Pi and pH is
thought to be due to an acute drug- induced hypotension
because the mean arterial blood pressure fell to 70% to 90%
of control within 10 to 15 minutes of intravenous injection of
IF [7 ].
Effect of Carbogen Breathing on IF Levels in Perchloric Acid
Extracts of Tumor and Normal Tissue by In Vitro 31P MRS
IF was detected in all tissues extracted, at a chemical
shift of +18 ppm relative to PCr. Levels of IF in the control
rats (air breathing) were between 0.14 and 0.27 mol/g
wet weight in all tissues except tumor, where levels were
0.06±0.01 mol/g wet weight. In tumor tissue in the rats
breathing carbogen, the IF levels were two- to threefold
higher at 0.17±0.03 mol/g (n=4, P<.02), whereas in all
other normal tissues studied, carbogen breathing caused
no significant changes (Table 2).
Discussion
These results show that all three gas regimes (carbogen,
2.5% CO2 in O2 and 5% CO2 in air ) caused an increase in IF
uptake into the tumor, probably because hypercapnic and/or
hyperoxic gas mixtures increase tumor blood volume. This is
consistent with the BOLD MRI data [18], where an increase
in image intensity caused by an increase in tumor oxygen-
ation and/or blood volume was observed with all three gas
regimes. In addition, the characteristic leakiness of tumor
blood vessels would also facilitate drug trapping.
Breathing carbogen (5% CO2 in O2) caused a greater
enhancement in IF uptake than either 2.5% CO2 in O2 or 5%
CO2 in air. Previous studies showed no differences in
radiotherapeutic response between 2% [16] and 2.5% [17]
CO2 in O2 when compared to carbogen breathing. Also,
breathing either 1% CO2, 2.5% CO2 in oxygen, or carbogen
caused responses of a similar magnitude in the transverse
relaxation rate (R2* ) measured by BOLD MRI when
compared to air breathing [18]. In tumors, the BOLD effect,
which is dependent on the endogenous paramagnetic
contrast agent, deoxyhemoglobin, is mediated by a complex
combination of oxygenation, blood flow, and blood volume
[5]. The lack of increase in the BOLD effect and radio-
sensitivity with carbogen breathing compared to 2.5% CO2 in
Table 2. Effect of Carbogen Breathing on IF Levels in Tumor and Normal
Tissue Extracts, Measured by 31P MRS.
Tissue IF (mol / g wet weight )
(Air Breathing )
IF (mol / g wet weight )
(Carbogen Breathing )
Tumor 0.057±0.01 0.166±0.03*
Liver 0.22±0.08 0.17±0.08
Spleen 0.2±0.02 0.17±0.05
Kidney 0.26±0.03 0.29±0.06
Muscle 0.2±0.04 0.18±0.02
Lung 0.27±0.07 0.22±0.08
Heart 0.14 0.18±0.02
Mean±SEM (n=3 or 4, except heart [ air breathing ] where n=2 ).
*P< .02.
Table 1. Effect of Breathing Different Gases on IF Pharmacokinetics in the
GH3 Prolactinoma Obtained from In Vivo 31P MRS Spectra.
T1 / 2 (min ) AUC
Air 274±67 16.3±3.6
5% CO2 in air 236±39 19.7±3.6
2.5% CO2 in O2 204±21 18±1.6
5% CO2 in O2 186±42* 17.7±3.9
Results show the mean±SEM (n=3 or 4 ), where T 1 / 2 is the half - life for
elimination and AUC is the area under ( IF /
P
P) versus time.
*P>.1 compared to air breathing.
Figure 4. Effect of intravenous IF ( 250 mg /kg ) on  -NTP /Pi (o) and pH
(6) in GH3 prolactinomas with the following breathing regimes: (A ) air,
(B ) 5% CO2 in air, (C ) 2.5% CO2 in O2, (D ) 5% CO2 in O2. Mean±SEM
(n=4 or 5 ).
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oxygen breathing can be explained in the following way: with
2.5% CO2 compared to 5% CO2 in carbogen, the oxygen–
hemoglobin dissociation curve will be shifted to the left,
thereby increasing the amount of oxygen bound to the
hemoglobin. This increased oxygen supply and lower
fraction of deoxyhemoglobin to the tumor capillary bed might
compensate for the reduced blood flow and blood volume
with lower (2.5%) CO2, leaving the BOLD effect and
radiosensitivity unchanged. However, in the present study,
the amount of drug ‘‘trapped’’ in the tumor would merely
depend on the fraction of CO2 in the gas mixture and the
degree of vasodilation and increase in blood volume that it
causes [5]. In the case of carbogen breathing, the oxygen
could cause vasoconstriction of normal tissue vasculature
but possibly not of tumor vessels, as the latter characteristi-
cally lack smooth muscle. The resistance of tumor vascula-
ture would decrease, increasing the blood volume and blood
flow [4] through the tumor tissue. Indeed, IF levels measured
in tissue extracts of normal tissue ( i.e., liver, spleen, muscle,
lung) were lower during carbogen breathing compared to air
breathing. When breathing 5% CO2 in air (20% oxygen),
hypercapnia induces systemic vasodilation in both normal
and tumor tissue. This could explain why the drug peaks at a
significantly later time in the tumor with the 5% CO2/95% air
regime than with the hyperoxic gas regimes in which the
vasoconstrictive effect of raised pO2 might compensate for
hypercapnia- induced vasodilation.
In conclusion, previous studies have shown that addition
of CO2 to hyperoxic gases has a beneficial effect with regard
to tumor oxygenation and tumor blood flow and the levels of
CO2 in carbogen gas mixtures can be reduced without
compromising the effect on oxygenation or radiosensitivity of
tumors or on the BOLD MRI changes. This study shows that
breathing high-content CO2 gases is suitable for increasing
the delivery of chemotherapeutic agents and although
breathing carbogen caused the largest increase in uptake
of IF, it was not significantly different from 2.5% CO2 in O2.
Therefore, the ability of 2.5% CO2 to enhance drug uptake to
the patient may be clinically useful as it causes less
discomfort (e.g., breathlessness) than 5% CO2, and thus,
patients’ tolerance may be increased.
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